{"ok":true,"nota":{"id":"36192d8af7a685c2","slug":"un-compuesto-experimental-potencio-la-respuesta-de-un-tratamiento-inmu-36192d","titulo":"Un compuesto experimental potenció la respuesta de un tratamiento inmunológico contra el cáncer de hígado en r","resumen":"Investigadores probaron un inhibidor de RORgamma en células de cáncer de hígado y en ratones. Según el estudio, redujo la llegada de neutrófilos, glóbulos blancos asociados a inflamación, y mejoró la respuesta a un fármaco de bloqueo de PD-L1.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Leo, S., Dhoparee-Doomah, I., Negi, S., Fouda, A., Bourdeau, F., Evaristo, G., Paraskevas, S., Cools-Lartigue, J., Tcher","url":"https://www.biorxiv.org/content/10.64898/2026.10.13.758999v1?rss=1","imagen":"/hoy/portada/36192d8af7a685c2","tema":"salud","subtemas":["cancer de higado","inmunoterapia","investigacion preclinica","inflamacion","farmacologia"],"entidades":["RORgamma"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-21T00:00:00.000Z","indexTs":"2026-10-21T16:39:55.345Z","hash":"460f340b989d7b2fd45f94984a2088eea7c54fe0399b749d195c2a38b1bc116c","tsa":{"time":"Oct 21 16:40:54 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"El cáncer de hígado tiene una de las tasas de sobrevida más bajas, y la inflamación alrededor del tumor se asocia a peores resultados. Si este compuesto llegara a humanos, podría sumar eficacia a inmunoterapias que hoy no funcionan en todos los pacientes. Pero el estudio es preclínico, en ratones, y de ahí a un tratamiento disponible hay muchas etapas. Por ahora es una pista de laboratorio, no una opción terapéutica.","quienFirma":"bioRxiv · preprints","confianza":"preprint","consulta":null},"sello":{"hash":"460f340b989d7b2fd45f94984a2088eea7c54fe0399b749d195c2a38b1bc116c","sello":"b26953b2342095a88fc1c0f0138a021a6b8a711afd903c3b4e70b2d7ce2cd1fd","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6572327,"aleatorio":"d83e967e4c34cdf1b7eff62e6ba3c2a80c045b63fe1850f9291b003cd2f10aa6","tiempo":"2026-10-21T16:40:30.000Z"},"nist":{"cadena":2,"pulso":1993369,"salida":"46902ECFB36399313FFB65B445E71293DBF949380A38ED8B222CF72E430037F81238506B220BC468F19AAF1083C6EF424CA492E1A3404D8F36DA9E790C7B253D","tiempo":"2026-10-21T16:40:00.000Z"},"noAntes":"2026-10-21T16:40:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 21 16:40:54 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Novel retinoic acid receptor-related orphan receptor gamma inverse agonist enhances checkpoint blockade in hepatocellular carcinoma: a preclinical mouse study","descripcion":"Background and Aims: Neutrophil-associated inflammation is associated with poor outcomes in hepatocellular carcinoma (HCC), but tumour-intrinsic regulators of neutrophil recruitment and checkpoint response remain unclear. We evaluated whether inhibiting retinoic acid receptor-related orphan receptor gamma (RORgamma) alters neutrophil recruitment, programmed death-ligand 1 (PD-L1) expression, and response to PD-L1 blockade. Approach and Results: Survival associations were analysed in The Cancer Genome Atlas HCC cohort. Neutrophil migration toward HCC cells and PD-L1 expression were assessed after RORC silencing or TF-S10 treatment. Immunocompetent mice bearing orthotopic Hep-55.1c tumours rec","pubDate":"2026-10-21","url":"https://www.biorxiv.org/content/10.64898/2026.10.13.758999v1?rss=1"},"indexado":"2026-10-21T16:39:55.345Z"}}